Última actualización 6 de julio de 2026
Key finding
FBS decreased significantly in the sitagliptin + metformin group compared to metformin alone (P = 0.030).
This study evaluated the effects of sitagliptin plus metformin therapy on metabolic profiles in patients with type 2 diabetes and NAFLD, finding significant improvements in various metabolic markers.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
This study evaluated the effects of sitagliptin plus metformin therapy on metabolic profiles in patients with type 2 diabetes and NAFLD, finding significant improvements in various metabolic markers.
The findings highlight the potential of combining sitagliptin with metformin to improve metabolic health in patients suffering from both type 2 diabetes and NAFLD. Given the rising prevalence of these conditions, effective treatment strategies are crucial for reducing long-term complications and improving patient outcomes.
The study's sample size may limit the generalizability of the findings. The duration of the intervention may not reflect long-term effects. Potential confounding factors were not fully controlled.
Published in
Publication details and source links for this paper.
Habib Y, Majid R, Niki K, Majid M, Narges ST. Sitagliptin Plus Metformin Therapy Improves Metabolic Profile in Patients with Type 2 Diabetes and NAFLD. Current Therapeutic Research, Clinical and Experimental. 2024;101:100764. doi:10.1016/j.curtheres.2024.100764
Fasting blood sugar decreased by 18 mg/dL in the sitagliptin + metformin group (P = 0.030).
Total cholesterol decreased by 58 mg/dL in the sitagliptin + metformin group (P = 0.017).
Triglycerides decreased by 93 mg/dL in the sitagliptin + metformin group (P = 0.008).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Dipeptidyl peptidase-4 inhibitors, Metformin and Alanine Aminotransferase (ALT), Fasting blood sugar (FBS), Glycemia risk index, and 3 more.
This study contributes evidence to
Primary intervention
Dipeptidyl peptidase-4 inhibitors
Primary outcomes
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
12
Evidence pairs
300
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Seguir evidencia
Relación de evidencia
Seguir evidencia
Core evidence
The primary outcomes reported in this study.
Dipeptidyl peptidase-4 inhibitors → Alanine Aminotransferase (ALT)
Dipeptidyl peptidase-4 inhibitors → Alanine Aminotransferase (ALT)
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Dipeptidyl peptidase-4 inhibitors → Fasting blood sugar (FBS)
Dipeptidyl peptidase-4 inhibitors → Glycemia risk index
Dipeptidyl peptidase-4 inhibitors → Glycemia risk index
Dipeptidyl peptidase-4 inhibitors → Serum vitamin D3 levels (Placebo)
Dipeptidyl peptidase-4 inhibitors → Serum vitamin D3 levels (Placebo)
Dipeptidyl peptidase-4 inhibitors → Total cholesterol
Dipeptidyl peptidase-4 inhibitors → Total cholesterol
Dipeptidyl peptidase-4 inhibitors → Triglycerides
Dipeptidyl peptidase-4 inhibitors → Triglycerides
Metformin → Alanine Aminotransferase (ALT)
Metformin → Alanine Aminotransferase (ALT)
Metformin → Serum vitamin D3 levels (Placebo)
Metformin → Serum vitamin D3 levels (Placebo)
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on DPP-4 Inhibitors and Adipokine and Angiogenic Markers, DPP-4 Inhibitors and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies on DPP-4 Inhibitors
Contributes to DPP-4 Inhibitors evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Metformin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies with generally consistent results and a positive effect signal.
Limitations
DPP-4 Inhibitors may improve Fasting Glucose.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Metformin Therapies may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Total cholesterol
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Triglycerides
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
DPP-4 Inhibitors appears to improve CGM Time in Range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Glycemia risk index
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Follow the topics this study contributes to.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.